The results showed that a single dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.
No detectable levels of infectious virus were observed in the lungs of vaccinated mice, representing a greater than one million-fold reduction compared to the non-vaccinated controls.
The ongoing Phase 1 trial evaluates the safety and immunogenicity of AdCOVID following a single dose or two intranasal doses administered one month apart.
Topline data is expected next month.
Price Action: ALT shares are up 4.37% at $13.85 during the premarket session on the last check Monday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.